LOG IN
SIGN UP
MARKET
VSTM
VSTM
Verastem
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.270
+0.030
+2.42%
After Hours: 1.240 -0.03 -2.36% 18:09 05/27 EDT
OPEN
1.240
PREV CLOSE
1.240
HIGH
1.300
LOW
1.234
VOLUME
805.88K
TURNOVER
0
52 WEEK HIGH
4.935
52 WEEK LOW
1.000
MARKET CAP
236.68M
P/E (TTM)
-3.0923
1D
5D
1M
3M
1Y
5Y
Verastem gets $3.8M award for VS-6766/defactinib combo trial to treat pancreatic cancer
Verastem Oncology (NASDAQ:VSTM) said it was selected to receive the first Therapeutic Accelerator Award of $3.8M from the Pancreatic Cancer Network (PanCAN). The Needham, Mass.-based company added that the award will
Seekingalpha · 05/18 13:15
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
BOSTON, May 18, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first "Therapeutic Accelerator Award" from the Pancreatic Cancer Net...
Business Wire · 05/18 12:45
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 05/16 12:16
Verastem Non-GAAP EPS of -$0.08 beats by $0.01, revenue of $2.6M beats by $1.1M
Verastem press release (NASDAQ:VSTM): Q1 Non-GAAP EPS of -$0.08 beats by $0.01. Revenue of $2.6M (+157.4% Y/Y) beats by $1.1M.
Seekingalpha · 05/09 21:12
-- Earnings Flash (VSTM) VERASTEM ONCOLOGY Posts Q1 Revenue $2.6M
MT Newswires · 05/09 16:48
-- Earnings Flash (VSTM) VERASTEM ONCOLOGY Reports Q1 Loss $-0.08
MT Newswires · 05/09 16:41
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 12:25
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Benzinga · 04/21 19:08
No Data
Learn about the latest financial forecast of VSTM. Analyze the recent business situations of Verastem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 5 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VSTM stock price target is 5.83 with a high estimate of 8.00 and a low estimate of 5.00.
Current 1.270
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Institutional Holdings
Institutions: 217
Institutional Holdings: 122.92M
% Owned: 65.96%
Shares Outstanding: 186.36M
TypeInstitutionsShares
Increased
40
9.04M
New
24
3.25M
Decreased
51
6.96M
Sold Out
20
2.58M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Operating Officer
Daniel Paterson
Chief Executive Officer/Director
Brian Stuglik
Chief Financial Officer
Robert Gagnon
Lead Director/Independent Director
Michael Kauffman
Independent Director
Paul Bunn
Independent Director
John Johnson
Independent Director
Michelle Robertson
Independent Director
Eric Rowinsky
Independent Director
Lesley Solomon
No Data
No Data
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.
Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.